Search

Search Constraints

You searched for: Author/Creator Arai, Taeang

Search Results

1. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. (22nd July 2021)

2. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (14th December 2022)

3. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. Issue 6 (19th February 2018)

4. Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Issue 11 (30th August 2022)

5. Association between vitamin D deficiency and pre‐existing resistance‐associated hepatitis C virus NS5A variants. Issue 7 (26th August 2016)

6. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Issue 5 (9th February 2022)

7. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Issue 7 (July 2019)

8. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Issue 2 (11th June 2021)

9. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023)

10. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Issue 7 (5th May 2021)